NCT06083103 Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)
| NCT ID | NCT06083103 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Paul Strauss |
| Condition | Cervical Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-10-12 |
| Primary Completion | 2026-09-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2023-10-12 with a primary completion date of 2026-09-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
\[18 F\]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging (PET/MRI) is a new hybrid imaging tool that has recently arrived in oncology, and is particularly promising. Its usefulness seems obvious in certain tumor types, but its place in the staging of cervical cancers has never been explored in a prospective trial to our knowledge. Previously, a comparative retrospective study from 2009 found a better sensitivity of PET fused to diagnostic MRI images compared to PET/CT (positron emission tomography/computed tomography) in the detection of metastatic lymph nodes (54 and 44% respectively). It was an a posteriori fusion of images, from images acquired by PET-CT.
Eligibility Criteria
Inclusion Criteria: * Patients aged from 18 years old and over * Patients with presumed cervical cancer of stages IB2 to IVA based on clinical data and pelvic MRI, undergoing pre-treatment assessment. * For women of childbearing potential : Adequate contraception throughout study participation. Note : enrollment in a concomitant clinical trial is authorized Exclusion Criteria: * Oncological history that could possibly interfere with imaging results interpretation, apart from cervical cancer * Extra-nodal metastasis clinically or radiologically proven before study participation * Contraindication to MRI or injection of contrast agents containing gadolinium * Contraindication to lumbo-aortic lymphadenectomy * Persons deprived of liberty * Minor or patients placed under guardianship or supervision * Patient under judicial protection * Patient unable to consent
Contact & Investigator
Éric OUVRARD, MD
STUDY CHAIR
Institut de cancérologie Strasbourg Europe
Frequently Asked Questions
Who can join the NCT06083103 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Cervical Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06083103 currently recruiting?
Yes, NCT06083103 is actively recruiting participants. Contact the research team at promotion-rc@icans.eu for enrollment information.
Where is the NCT06083103 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT06083103 clinical trial?
NCT06083103 is sponsored by Centre Paul Strauss. The principal investigator is Éric OUVRARD, MD at Institut de cancérologie Strasbourg Europe. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.